Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK.
Eur Urol. 2019 Aug;76(2):151-156. doi: 10.1016/j.eururo.2019.05.022.
Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. PATIENT SUMMARY: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.
最近的随机临床试验表明，在转移性透明细胞肾细胞癌中，一线伊匹单抗和纳武单抗联合治疗，以及派姆单抗和阿昔替尼联合治疗具有生存获益。欧洲泌尿外科学会指南小组根据这些研究更新了其建议。
派姆单抗联合阿昔替尼是一种新的治疗标准，适用于诊断为肾癌已扩散至肾脏以外且未接受任何先前癌症治疗（无治疗史）的患者。根据国际转移性肾细胞癌数据库联盟标准确定的所有风险组均适用。
